What do systematic reviews say?

Postoperative MMC‐EMDA with sequential BCG induction and maintenance vs postoperative BCG induction and maintenance therapy

The review found no eligible studies for this question.

• Intravesical electromotive drug administration for non‐muscle invasive bladder cancer 2017 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Single‐dose, preoperative MMC‐EMDA vs single‐dose, postoperative MMC‐PD

The review found no eligible studies for this question.

• Intravesical electromotive drug administration for non‐muscle invasive bladder cancer 2017 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Single‐dose, preoperative MMC‐EMDA vs TURBT alone

The review found no eligible studies for this question.

• Intravesical electromotive drug administration for non‐muscle invasive bladder cancer 2017 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Postoperative MMC‐EMDA induction vs postoperative BCG induction therapy

The review found no eligible studies for this question.

• Intravesical electromotive drug administration for non‐muscle invasive bladder cancer 2017 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Intravesically administered BCG alternating with IFN‐α vs intravesically administered BCG alone

The review found no eligible studies for this question.

• Intravesical Bacillus Calmette‐Guérin with interferon‐alpha versus intravesical Bacillus Calmette‐Guérin for treating… 2017 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Intravesically administered BCG combined with IFN‐α vs intravesically administered BCG alone

The review found no eligible studies for this question.

• Intravesical Bacillus Calmette‐Guérin with interferon‐alpha versus intravesical Bacillus Calmette‐Guérin for treating… 2017 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Antimicrobial lozenge vs placebo

• Pharmacological interventions for preventing dry mouth and salivary gland dysfunction following radiotherapy 2017 · Cochrane All outcomes

  Over 6 months
  Insufficient evidence of a difference for global quality of life, mouth pain RR 0.94 (95% CI 0.66 to 1.33), sore/burning mouth RR 0.95 (95% CI 0.68 to 1.35), throat pain RR 0.79 (95% CI 0.56 to 1.12) (Duncan 2005)
  1 study
  GRADE not reported

Intervention not reported

• Acupuncture for neck disorders 2016 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 3451 participants
  GRADE not reported

Acupuncture vs placebo

It is very uncertain whether acupuncture changes quality of life: anxiodepressive symptomatology compared with placebo (very low certainty).

• Interventions for treating hyperemesis gravidarum 2016 · Cochrane Headline outcomes only
  RR 1.01 [0.73, 1.4]
  1 study · 36 participants
  Very low

Enhanced recovery protocol vs usual care

• Enhanced recovery protocols for major upper gastrointestinal, liver and pancreatic surgery 2016 · Cochrane Headline outcomes only
  no estimate extracted
  4 studies · 373 participants
  Very low

Intervention not reported

The review found no eligible studies for this question.

• Photodynamic therapy for recurrent respiratory papillomatosis 2014 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Beclometasone/LABA vs LABA

• Beclometasone for chronic obstructive pulmonary disease 2013 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 465 participants
  Moderate

Dopamine agonist vs placebo

• Dopamine agonists for the treatment of restless legs syndrome 2011 · Cochrane Headline outcomes only
  no estimate extracted
  17 studies · 4312 participants
  Moderate

Rituximab vs intravenous methylprednisolone

• Rituximab for thyroid‐associated ophthalmopathy 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 27 participants
  Very low

Summary of findings table ‐ Systemic therapy vs control

• Systemic therapies for preventing or treating aromatase inhibitor‐induced musculoskeletal symptoms in early breast… 2022 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 208 participants
  Very low

Complex information, support and training interventions vs inactive control (usual care care, attention control, waitlist)

• Remotely delivered information, training and support for informal caregivers of people with dementia 2021 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 311 participants
  Moderate

Complex information, support and training interventions vs information only

• Remotely delivered information, training and support for informal caregivers of people with dementia 2021 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 257 participants
  Low

Sertraline vs cognitive behavioural therapy

• Antidepressants for people with epilepsy and depression 2021 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 118 participants
  Moderate

Anti‐IgE mAb (omalizumab) vs placebo (on top of topical steroids)

• Biologics for chronic rhinosinusitis 2021 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 38 participants
  Very low

Phlebotonics vs placebo?

• Phlebotonics for venous insufficiency 2020 · Cochrane Headline outcomes only
  no estimate extracted
  5 studies · 1639 participants
  Moderate